Trial Profile
A Phase I Study of Cyclic Oral Administration of SCH 52365 [temozolomide] for 21 of 28 Days in Patients With Advanced Solid Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Cancer metastases; Glioblastoma; Solid tumours
- Focus Adverse reactions
- 27 Sep 2005 New trial record.